Yajie Lu1, Xiao Lu2, Minghui Li1, Xiantao Chen3, Youwen Liu3, Xianfa Feng4, Jinwei Yu5, Chengquan Zhang6, Dongsheng Niu7, Siqun Wang8, Zhen Wang9, Jianxi Lu10. 1. Department of Orthopedics, Xijing Hospital, The Air Force Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi, China. 2. School of Materials Science and Engineering, South China University of Technology, No.381 Wuhan Road, Guangzhou, Guangdong, China. 3. Luoyang Orthopedic Hospital of Henan Province, No. 82 Qiming South Road, Luoyang, Henan, China. 4. Central Hospital of Songyuan City, No.1188 Wenhua Road, Songyuan, Jilin, China. 5. Second People's Hospital of Jiaozuo City, No.17 Minzhu South Road, Jiaozuo, Henan, China. 6. Central Hospital of Hanzhong City, No. 22 Kangfu Road, Hanzhong, Shaanxi, China. 7. Ningxia People's Hospital, No. 301 Zhengyuan North Road, Yinchuan, Ningxia, China. 8. Huashan Hospital of Fudan University, No.12 Urumqi Middle Road, Shanghai, China. 9. Department of Orthopedics, Xijing Hospital, The Air Force Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi, China. wangzhen@fmmu.edu.cn. 10. Shanghai Bio-lu Biomaterials Co., Ltd., No.188 Xinjunhuan Road, Shanghai, China. lujianxi888@hotmail.com.
Abstract
PURPOSE: To describe the rationale, the surgical technique, and the short-term follow-up results of a new minimally invasive treatment of osteonecrosis of the femoral head (ONFH) with an angioconductive bioceramic rod (ABR) implant. METHODS: Sixty-two patients (72 hips) with ARCO stage IIA-IIIC ONFH treated with the minimally invasive ABR from January 2012 to December 2016 were reviewed (17 females, 45 males, mean age 44.49). This technique used the angioconductive properties of the porous implant to repair the necrosis by driving vascularization from the trochanter to the necrotic area. Patients had a mean follow-up period of 26.74 months. The outcomes were evaluated by hip joint survival, radiograph, and the Harris Hip Score (HHS). The complications occurred during the treatment period were recorded. RESULTS: No serious post-operative complications occurred during the treatment. The overall joint survival rate was 90.27%, with seven conversions to THA. Improvements were observed in 23 (31.95%) hips, 24 (33.33%) hips remained stable, and 25 (34.72%) hips had worse results according to the radiographic evaluation. The mean HHS at the end follow-up significantly improved compared to the pre-operative mean HHS (82.27 vs 58.14, p < 0.001). In both radiographic evaluation and HHS, the treatment was more effective on patients beneath 44 years old (p < 0.05); ARCO stage II compared to stage III (p < 0.05); and China-Japan Friendship Hospital (CJFH) type C compared to CJFH type L (p < 0.05). CONCLUSIONS: The minimally invasive treatment of ONFH with ABR showed promising results in delaying or even terminating the progression of the necrosis and improving hip function, especially in younger patients and in the early stages of the disease.
PURPOSE: To describe the rationale, the surgical technique, and the short-term follow-up results of a new minimally invasive treatment of osteonecrosis of the femoral head (ONFH) with an angioconductive bioceramic rod (ABR) implant. METHODS: Sixty-two patients (72 hips) with ARCO stage IIA-IIIC ONFH treated with the minimally invasive ABR from January 2012 to December 2016 were reviewed (17 females, 45 males, mean age 44.49). This technique used the angioconductive properties of the porous implant to repair the necrosis by driving vascularization from the trochanter to the necrotic area. Patients had a mean follow-up period of 26.74 months. The outcomes were evaluated by hip joint survival, radiograph, and the Harris Hip Score (HHS). The complications occurred during the treatment period were recorded. RESULTS: No serious post-operative complications occurred during the treatment. The overall joint survival rate was 90.27%, with seven conversions to THA. Improvements were observed in 23 (31.95%) hips, 24 (33.33%) hips remained stable, and 25 (34.72%) hips had worse results according to the radiographic evaluation. The mean HHS at the end follow-up significantly improved compared to the pre-operative mean HHS (82.27 vs 58.14, p < 0.001). In both radiographic evaluation and HHS, the treatment was more effective on patients beneath 44 years old (p < 0.05); ARCO stage II compared to stage III (p < 0.05); and China-Japan Friendship Hospital (CJFH) type C compared to CJFH type L (p < 0.05). CONCLUSIONS: The minimally invasive treatment of ONFH with ABR showed promising results in delaying or even terminating the progression of the necrosis and improving hip function, especially in younger patients and in the early stages of the disease.
Authors: Anton Y Plakseychuk; Shin-Yoon Kim; Byung-Chul Park; Sokratis E Varitimidis; Harry E Rubash; Dean G Sotereanos Journal: J Bone Joint Surg Am Date: 2003-04 Impact factor: 5.284
Authors: Michael A Mont; Hytham S Salem; Nicolas S Piuzzi; Stuart B Goodman; Lynne C Jones Journal: J Bone Joint Surg Am Date: 2020-06-17 Impact factor: 6.558
Authors: Matthew J Smith; Sandi G Dempsey; Robert Wf Veale; Claudia G Duston-Fursman; Chloe A F Rayner; Chettha Javanapong; Dane Gerneke; Shane G Dowling; Brandon A Bosque; Tanvi Karnik; Michael J Jerram; Arun Nagarajan; Ravinder Rajam; Alister Jowsey; Samuel Cutajar; Isaac Mason; Roderick G Stanley; Andrew Campbell; Jenny Malmstrom; Chris H Miller; Barnaby C H May Journal: J Biomater Appl Date: 2021-11-07 Impact factor: 2.646